Kraig Biocraft Laboratories, Inc. Announces That It Has Successfully Created Transgenic Silkworm

LANSING, MI--(Marketwire - September 07, 2010) - Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that scientists working in collaboration with the Company have successfully created transgenic silkworms. The silkworms were successfully genetically engineered with targeted spider silk DNA sequences.

“We are very excited to be able to announce our genetic engineering success,” said CEO Kim K. Thompson. “The creation of these transgenics was greeted with much celebration among the scientists and in the corporate office. In my view our accomplishment establishes that we have been on the right track all along. This achievement is a landmark event for the Company. It clears a major hurdle in our path and puts us well ahead of our development schedule.”

In addition to the news released today, the Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month. Earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.


CONTACT:
Kraig Biocraft Laboratories, Inc.
Kim K. Thompson
CEO
(517) 336-0807
Email Contact

MORE ON THIS TOPIC